🚀 VC round data is live in beta, check it out!
Atea Pharmaceuticals Valuation Multiples
Discover revenue and EBITDA valuation multiples for Atea Pharmaceuticals and similar public comparables like Forte Biosciences, Medy-Tox, Genfit, YungShin Global Holding and more.
Atea Pharmaceuticals Overview
About Atea Pharmaceuticals
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
Founded
2012
HQ
Employees
56
Website
Sectors
Financials (LTM)
EV
$165M
Atea Pharmaceuticals Financials
Atea Pharmaceuticals reported last 12-month revenue of — and negative EBITDA of ($166M).
In the same LTM period, Atea Pharmaceuticals generated ($166M) in EBITDA losses and had net loss of ($163M).
Revenue (LTM)
Atea Pharmaceuticals P&L
In the most recent fiscal year, Atea Pharmaceuticals reported revenue of — and EBITDA of ($160M).
Atea Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | ($166M) | XXX | ($160M) | XXX | XXX | XXX |
| Net Profit | ($163M) | XXX | ($158M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Atea Pharmaceuticals Stock Performance
Atea Pharmaceuticals has current market cap of $466M, and enterprise value of $165M.
Market Cap Evolution
Atea Pharmaceuticals' stock price is $5.85.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $165M | $466M | -1.5% | XXX | XXX | XXX | $-1.99 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAtea Pharmaceuticals Valuation Multiples
Atea Pharmaceuticals trades at (1.0x) EV/EBITDA.
EV / Revenue (LTM)
Atea Pharmaceuticals Financial Valuation Multiples
As of April 11, 2026, Atea Pharmaceuticals has market cap of $466M and EV of $165M.
Equity research analysts estimate Atea Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Atea Pharmaceuticals has a P/E ratio of (2.9x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $466M | XXX | $466M | XXX | XXX | XXX |
| EV (current) | $165M | XXX | $165M | XXX | XXX | XXX |
| EV/EBITDA | (1.0x) | XXX | (1.0x) | XXX | XXX | XXX |
| EV/EBIT | (1.0x) | XXX | (1.0x) | XXX | XXX | XXX |
| P/E | (2.9x) | XXX | (2.9x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (1.3x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Atea Pharmaceuticals Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Atea Pharmaceuticals Margins & Growth Rates
Atea Pharmaceuticals' revenue in the last fiscal year grew by —.
Atea Pharmaceuticals' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $3.2M for the same period.
Atea Pharmaceuticals Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | (3%) | XXX | 14% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $3.2M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Atea Pharmaceuticals Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Forte Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Medy-Tox | XXX | XXX | XXX | XXX | XXX | XXX |
| Genfit | XXX | XXX | XXX | XXX | XXX | XXX |
| YungShin Global Holding | XXX | XXX | XXX | XXX | XXX | XXX |
| Kamada | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Atea Pharmaceuticals M&A Activity
Atea Pharmaceuticals acquired XXX companies to date.
Last acquisition by Atea Pharmaceuticals was on XXXXXXXX, XXXXX. Atea Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Atea Pharmaceuticals
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAtea Pharmaceuticals Investment Activity
Atea Pharmaceuticals invested in XXX companies to date.
Atea Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. Atea Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Atea Pharmaceuticals
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Atea Pharmaceuticals
| When was Atea Pharmaceuticals founded? | Atea Pharmaceuticals was founded in 2012. |
| Where is Atea Pharmaceuticals headquartered? | Atea Pharmaceuticals is headquartered in United States. |
| How many employees does Atea Pharmaceuticals have? | As of today, Atea Pharmaceuticals has over 56 employees. |
| Who is the CEO of Atea Pharmaceuticals? | Atea Pharmaceuticals' CEO is Jean-Pierre Sommadossi. |
| Is Atea Pharmaceuticals publicly listed? | Yes, Atea Pharmaceuticals is a public company listed on Nasdaq. |
| What is the stock symbol of Atea Pharmaceuticals? | Atea Pharmaceuticals trades under AVIR ticker. |
| When did Atea Pharmaceuticals go public? | Atea Pharmaceuticals went public in 2020. |
| Who are competitors of Atea Pharmaceuticals? | Atea Pharmaceuticals main competitors are Forte Biosciences, Medy-Tox, Genfit, YungShin Global Holding. |
| What is the current market cap of Atea Pharmaceuticals? | Atea Pharmaceuticals' current market cap is $466M. |
| Is Atea Pharmaceuticals profitable? | No, Atea Pharmaceuticals is not profitable. |
| What is the current EBITDA of Atea Pharmaceuticals? | Atea Pharmaceuticals has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of Atea Pharmaceuticals? | Current EBITDA multiple of Atea Pharmaceuticals is (1.0x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.